v3.25.2
Condensed Consolidated Statements of Shareholders’ Equity - USD ($)
$ in Thousands
Total
At-The-Market Offering
ADDITIONAL PAID-IN CAPITAL
ADDITIONAL PAID-IN CAPITAL
At-The-Market Offering
ACCUMULATED OTHER COMPREHENSIVE (LOSS)/INCOME
ACCUMULATED DEFICIT
Ordinary shares
COMMON STOCK
Ordinary shares
COMMON STOCK
At-The-Market Offering
Beginning balance (in shares) at Dec. 31, 2023             61,943,471  
Beginning balance at Dec. 31, 2023 $ 225,744   $ 621,645   $ (16,926) $ (379,610) $ 635  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Exercise of share options (in shares)             86,510  
Exercise of share options 220   219       $ 1  
Issuance of ordinary shares, net of issuance costs (in shares)               2,509,798
Issuance of ordinary shares, net of issuance costs   $ 26,219   $ 26,194       $ 25
Issuance of ordinary shares to settle vested restricted stock units (in shares)             50,705  
Issuance of ordinary shares to settle vested restricted stock units 0              
Issuance of ordinary shares to settle warrants exercised (in shares)             3,752,050  
Issuance of ordinary shares to settle warrants exercised 37,258   37,220       $ 38  
Shares tendered for withholding taxes (185)   (185)          
Share-based compensation expense 5,129   5,129          
Unrealized loss on foreign currency translation (36)       (36)      
Net loss (35,187)         (35,187)    
Ending balance (in shares) at Mar. 31, 2024             68,342,534  
Ending balance at Mar. 31, 2024 259,162   690,222   (16,962) (414,797) $ 699  
Beginning balance (in shares) at Dec. 31, 2023             61,943,471  
Beginning balance at Dec. 31, 2023 225,744   621,645   (16,926) (379,610) $ 635  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Unrealized loss on foreign currency translation 45              
Net loss (73,288)              
Ending balance (in shares) at Jun. 30, 2024             68,387,469  
Ending balance at Jun. 30, 2024 226,273   695,353   (16,881) (452,898) $ 699  
Beginning balance (in shares) at Mar. 31, 2024             68,342,534  
Beginning balance at Mar. 31, 2024 259,162   690,222   (16,962) (414,797) $ 699  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Exercise of share options (in shares)             3,845  
Exercise of share options 0              
Issuance of ordinary shares to settle vested restricted stock units (in shares)             4,438  
Issuance of ordinary shares to settle vested restricted stock units 0              
Vesting of equity awards under the employee purchase plan ( in shares)             36,652  
Vesting of equity awards under the employee purchase plan 210   210          
Share-based compensation expense 4,921   4,921          
Unrealized loss on foreign currency translation 81       81      
Net loss (38,101)         (38,101)    
Ending balance (in shares) at Jun. 30, 2024             68,387,469  
Ending balance at Jun. 30, 2024 $ 226,273   695,353   (16,881) (452,898) $ 699  
Beginning balance (in shares) at Dec. 31, 2024 68,552,215           68,552,215  
Beginning balance at Dec. 31, 2024 $ 154,695   704,919   (16,194) (534,732) $ 702  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Exercise of share options (in shares)             164,422  
Exercise of share options 2           $ 2  
Issuance of ordinary shares, net of issuance costs (in shares)               24,014,728
Issuance of ordinary shares, net of issuance costs   $ 54,816   $ 54,583       $ 233
Issuance of ordinary shares to settle vested restricted stock units (in shares)             116,961  
Issuance of ordinary shares to settle vested restricted stock units 0   (1)       $ 1  
Share-based compensation expense 3,935   3,935          
Unrealized loss on foreign currency translation (117)       (117)      
Net loss (17,864)         (17,864)    
Ending balance (in shares) at Mar. 31, 2025             92,848,326  
Ending balance at Mar. 31, 2025 $ 195,467   763,436   (16,311) (552,596) $ 938  
Beginning balance (in shares) at Dec. 31, 2024 68,552,215           68,552,215  
Beginning balance at Dec. 31, 2024 $ 154,695   704,919   (16,194) (534,732) $ 702  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Unrealized loss on foreign currency translation 1,612              
Net loss $ (56,267)              
Ending balance (in shares) at Jun. 30, 2025 93,586,348           93,586,348  
Ending balance at Jun. 30, 2025 $ 162,555   767,190   (14,582) (590,999) $ 946  
Beginning balance (in shares) at Mar. 31, 2025             92,848,326  
Beginning balance at Mar. 31, 2025 195,467   763,436   (16,311) (552,596) $ 938  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Exercise of share options (in shares)             682,682  
Exercise of share options 9   2       $ 7  
Issuance of ordinary shares to settle vested restricted stock units (in shares)             9,375  
Issuance of ordinary shares to settle vested restricted stock units 0              
Vesting of equity awards under the employee purchase plan ( in shares)             45,965  
Vesting of equity awards under the employee purchase plan 157   156       $ 1  
Share-based compensation expense 3,596   3,596          
Unrealized loss on foreign currency translation 1,729       1,729      
Net loss $ (38,403)         (38,403)    
Ending balance (in shares) at Jun. 30, 2025 93,586,348           93,586,348  
Ending balance at Jun. 30, 2025 $ 162,555   $ 767,190   $ (14,582) $ (590,999) $ 946